BioPartnering North America

BioPartnering North America

December 18, 2006 14:05 ET

BioPartnering North America Highlights the Hottest Themes in Biotech Today

SANTA CRUZ, CALIFORNIA--(CCNMatthews - Dec. 18, 2006) - Technology Vision Group LLC (TVG) is pleased to announce program details for the 5th Annual BioPartnering North America (BPN: http://www.techvision.com/bpn) conference which will be held in Vancouver, B.C., Canada on February 4-6, 2007 as a partnership between TVG, BC Biotech, BioAlberta, and BIOTECanada. One of the hallmarks of BPN, and reasons for its continued success, is its innovative and informative program which features some of the hottest themes in the biotech industry today.

This year's program will present five BioPartnering Leadership Sessions, six Sponsor Workshops and 78 company presentations that aim to highlight key issues and themes through topical debate, as well as providing the perfect platform for biotech companies seeking potential partners and business opportunities. BioPartnering North America consistently attracts the key decision makers from the global biotechnology, pharmaceutical and financial industries.

For full details of how to register for BPN, and take advantage of the Early Bird delegate rate (available until January 2nd 2007) please see http://www.techvision.com/bpn/registration/

BioPartnering Leadership Sessions Address Cutting Edge Themes

One of the key features of BPN are the BioPartnering Leadership Sessions, where some of the most important issues effecting the growth of the life-science industry today are debated by a group of key decision makers. One of this year's sessions, entitled "Lessons Learned from M&A Wars", will see an expert panel giving the audience their insights into the creation, implementation, and impact of M&A deals. The panel will discuss how to prepare your company for an M&A deal including how to select and approach the targets, the intricacies of negotiating the legal documentation for an M&A deal; provide opinions on how equity research analysts treat companies in the M&A game; as well as shared views on how the capital markets facilitate M&A transactions and future financings for successful acquirers.

Other sessions in this series will look at:

- Creative Deal Making

- The impact of Partnering on Liquidity Events

- Getting the Deal You Need

- The Future of Biotechnology Deal-Making

G. Collet, Director of Business Development at AstraZeneca commented, "BPN is probably the best organized meeting available. It is always well attended as it addresses the current issues that face the industry. It provides experienced and credible panels and presenters. BPN provides a real service to the life science industry."

Open House Series Features Interactive Presentations

Another popular feature of BPN are the Open House presentations, where 56 emerging biopharmaceutical and diagnostic companies will host 2.5 hour interactive multimedia sessions designed to combine the detailed information of a podium presentation with the feel of a business development meeting.

TVG is still accepting applications to present, which can be submitted online at www.techvision.com/bpn/registration/presenter/apply.php

biopartnering.com & Video Profiles Foster B2B Opportunities

BPN delegates will once again be able to search partnering opportunities through keyword searches of detailed profiles on all companies, contact other delegates, arrange private meetings, and reserve meeting rooms in advance of the conference. In addition, biopartnering.com now offers a unique component - video profiles. This feature will give Open House and Emerging Company presenters the ability to add a short video to their biopartnering.com profile, promoting their company in a dynamic and engaging manner.

Full details about BioPartnering North America online at: http://www.techvision.com/bpn

Conference Sponsors

Angiotech Pharmaceuticals, Inc., AstraZeneca, PricewaterhouseCoopers, Province of British Columbia, Cooley Godward Kronish LLP, Farris, Vaughan, Wills & Murphy LLP, Ferghana Partners Group, Morrison & Foerster, Pfizer, Bristol-Myers Squibb Company, Merck & Co., Inc., NovaQuest, Novartis, QLT Inc., Roche, Seed Intellectual Property Law Group PLLC, UK Trade & Investment, anapharm, BC Innovation Council, BioWa, Inc., Genome British Columbia, Hong Kong Science and Technology Parks, Life Science Analytics, Marsh Canada Limited, UBC University - Industry Liaison Office

Conference Supporters

Bio Business, BioExecutive International, Biotechnology Focus, BioWorld Today, CCNMatthews , Citigate Dewe Rogerson, Contact Canada®, European Biopharmaceutical Review, Nature Biotechnology, U.S. Commercial Service, Global Bioscience Partnership

2007 Emerging Company Presenters

Acretia Inc., Amkor Pharma, Inc., Aquinox Pharmaceuticals, Clone-E Therapeutics, Colby Pharmaceuticals, EUSA Pharma Inc, FoldRx Pharmaceuticals, GammaCan Int. Inc., Jennerex Biotherapeutics Inc., Kinexis Inc., MAP Pharmaceuticals, Merrion Pharmaceuticals Limited, Nerities Corporation, PainCeptor Pharma Corp., Royalmount Pharma, Taligen Therapeutics

2007 Open House Presenters

Aegera Therapeutics Inc., Affibody, Alimentary Health Ltd, Alphora Research Inc., Aspreva Pharmaceuticals, Athenagen, Avid Bioservices, Axela Biosensors Inc., BioWa, Inc., BIOZONA, Cell Genesys, Inc., Celldex Therapeutics, Centre for Translational and Applied Genomics, ChemokineTherapeutics, CombinatoRx, Cytokinetics, Inc., decode Chemistry & Biostructures, enGene, Enzo Therapeutics, Inc., Epeius Biotechnologies Corporation, F2G Limited,
Forbes Medi-Tech Inc., Hunter-Fleming Limited, Ichor Medical Systems, Inc., Ingenium Pharmaceuticals AG, Inimex Pharmaceuticals, Inc., InNexus Biotechnology Inc., KAI Pharmaceuticals, Lorus Therapeutics, Inc., MaxCyte, Inc., Miltenyi Bioprocess, NAL Pharmaceuticals Ltd, NascaCell Technologies AG, Naviscan PET Systems, NovaDel Pharma, NPIL Pharma Torcan, Orphan Australia Pty Ltd, Patheon Inc., PIERIS AG, Protox Therapeutics, Inc., Resverlogix Corp., SemBioSys, SR Pharma plc. / Atugen AG, Stem Cell Therapeutics, Syntaxin, Tripos Discovery Research, Vertical i, Inc., Virxsys Corporation, Welichem Biotech Inc., XOMA Ltd., Xytis, ZIOPHARM Oncology, Inc.

Contact Information